Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology
Go back to Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1217.15 -14.79 (1.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1231.94 | 52 Week High | $88.16 | |||
| Open | $1230.65 | 52 Week Low | $67.88 | |||
| Day High | $1238.00 | P/E | 281.75 | |||
| Day Low | $1210.01 | EPS | $4.32 | |||
| Volume | 1,092,917 | |||||
